JMP Securities Healthcare Focus conference Oct. 7-8
Cowen & Co. 12 th Annual Therapeutics Conference Oct. 8
FDA approval decision date for Spectrum Pharmaceuticals' ( SPPI) colon cancer drug Fusilev. Oct. 13
Presentation at the American Neurological Association meeting of detailed data from the phase III study of Avanir Pharmaceuticals' ( AVNR) Zenvia, an experimental drug for the treatment of uncontrollable laughing and crying episodes -- a condition known medically as pseudobulbar affect. Avanir announced positive top-line results from this study in August.
Third-quarter earnings: Johnson & Johnson ( JNJ) (before market open) and Gilead Sciences ( GILD) (after market close.) Oct. 14
The FDA's Peripheral and Central Nervous System Drug Advisory Committee will convene to review Acorda Therapeutics' ( ACOR) fampridine (brand name Amaya). The proposed indication for Amaya is to improve the walking ability of patients with multiple sclerosis. Biogen Idec ( BIIB) is Acorda's marketing partner for Amaya.
Take note: The FDA's briefing documents for Amaya should be posted to the agency's web site on Oct. 12 or 13. When available, those documents can be found here.
Third-quarter earnings: Abbott Labs ( ABT) (before market open.) Oct. 15
Third-quarter earnings: Cubist Pharmaceuticals ( CBST) (after market closes.) Oct. 16-21
The American College of Rheumatology annual meeting in Philadelphia. Noteworthy clinical data expected for presentation includes Pfizer's ( PFE) CP-690550 in rheumatoid arthritis and Rigel Pharmaceuticals' ( RIGL) R788 in rheumatoid arthritis Oct. 19
FDA approval decision date for Amgen's ( AMGN) osteoporosis drug denosumab. If approved, Amgen will market the drug under the brand name Prolia. Oct. 22
FDA's approval decision date for Acorda's drug Amaya. Oct. 24-28
The Obesity Society annual meeting convenes in Washington, D.C. Detailed data from phase III studies of three closely watched weight-loss drugs will be presented at the meeting: Arena Pharmaceuticals' ( ARNA) lorcaserin, Vivus' ( VVUS) Qnexa and Orexigen Therapeutics' ( OREX) Contrave.
FDA approval decision date for GTX's ( GTXI) Acapodene for the reduction of bone fractures in prostate cancer patients undergoing androgen deprivation therapy.
FDA approval decision date for Transcept Pharmaceuticals' ( TSPT) Intermezzo for insomnia. Oct. 30-Nov. 4
The American Association for the Study of Liver Disease convenes in Boston. This is the most important meeting for hepatitis C drug research held on the U.S. every year. Stocks to watch include Vertex Pharmaceuticals ( TICKER) ( VRTX), InterMune ( ITMN), Pharmasset ( VRUS), Idenix Pharmaceuticals ( IDIX) and Anadys Pharmaceuticals ( ANDS). Important clinical trials with potential data readouts or other biotech events expected in October: Company: Protalix BioTherapeutics ( PLX)
Drug/indication: prGCD (Uplyso) in Gaucher's disease. Company: Allos Therapeutics ( ALTH)
Commercial launch of Folotyn in peripheral T-cell lymphoma Written by Adam Feuerstein in Boston